Innospec vs Stepan
Stepan reported revenue of $2.3 billion in fiscal 2025, 1.3 times Innospec's $1.8 billion in fiscal 2025. Innospec's revenue fell 3.6% in its latest year, and Stepan's grew 7.0%. Innospec had an operating margin of 7.3%, against 3.4% at Stepan. Free cash flow was $88 million at Innospec and $25 million at Stepan.
Side by side
| Innospec | Stepan | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.8B | $2.3B |
| Revenue growth | −3.6% | 7.0% |
| Revenue growth a year, last 5 years | 8.3% | 4.5% |
| Gross margin | 27.7% | 11.6% |
| Operating margin | 7.3% | 3.4% |
| Net margin | 6.6% | 2.0% |
| Free cash flow | $88M | $25M |
| Free cash flow margin | 5.0% | 1.1% |
| Return on capital | 11.1% | 3.6% |
| Net debt to EBITDA | −1.7x | 2.4x |
| Dividends and buybacks | $66M | $35M |
| Change in diluted share count | −0.5% | −0.2% |
| Last close | $99.18 | $64.77 |
| P/E at the last close | 20.2× | — |
| Insider trades, last 12 months | bought $25,191, sold $398,854 | — |
| Piotroski F-score | 6 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
InnospecStepan
Operating margin
Percent of revenue
InnospecStepan
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InnospecStepan